新型三价铬对高血糖胰岛素缺乏大鼠的降血糖效力

Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats.

作者信息

Machaliński Bogusław, Walczak Mieczysław, Syrenicz Anhelli, Machalińska Anna, Grymuła Katarzyna, Stecewicz Iwona, Wiszniewska Barbara, Dabkowska Elzbieta

机构信息

Department of General Pathology, Clinic of Pediatrics, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

出版信息

J Trace Elem Med Biol. 2006;20(1):33-9. doi: 10.1016/j.jtemb.2006.01.002. Epub 2006 Mar 3.

DOI:10.1016/j.jtemb.2006.01.002

PMID:16632174

Abstract

Two sources of chromium III, "chromium 454" and "chromium picolinate," were tested in insulin-deficient Streptozocin-treated diabetic rats. This model was selected in order to evaluate the possibility of any hypoglycemic potency of chromium in a relative absence of blood insulin concentration. Three weeks of the treatment with CRC454 and CrP resulted in a 38% and 11% reduction of blood glucose levels, respectively. Body weight gains were equally improved by both treatments. Blood levels of CK, ALT and AST were significantly reduced by CRC454 and CrP. These results might suggest that any hypoglycemic effect of trivalent chromium under insulin-deficient conditions could be largely dependent upon the type of chromium agent and associated characteristics such as solubility and bioavalibility. In contrast, improvement of body weight gains and blood levels of CK, AST and ALT seems to be less dependent on the type of chromium compound under these experimental conditions. In conclusion, CRC454 showed significant reduction of hyperglycemia under insulin-deficient conditions.

摘要

在链脲佐菌素诱导的胰岛素缺乏型糖尿病大鼠中，对两种三价铬来源“铬454”和“吡啶甲酸铬”进行了测试。选择该模型是为了评估在相对缺乏血胰岛素浓度的情况下，铬的任何降血糖效力的可能性。用铬454（CRC454）和吡啶甲酸铬（CrP）治疗三周后，血糖水平分别降低了38%和11%。两种治疗对体重增加的改善效果相同。铬454和吡啶甲酸铬显著降低了血液中肌酸激酶（CK）、谷丙转氨酶（ALT）和谷草转氨酶（AST）的水平。这些结果可能表明，在胰岛素缺乏的情况下，三价铬的任何降血糖作用可能在很大程度上取决于铬制剂的类型以及相关特性，如溶解度和生物利用度。相比之下，在这些实验条件下，体重增加以及血液中肌酸激酶、谷草转氨酶和谷丙转氨酶水平的改善似乎较少依赖于铬化合物的类型。总之，在胰岛素缺乏的情况下，铬454显示出显著降低高血糖的作用。